Hagop M. Kantarjian
Hagop M. Kantarjian publishes mostly in Hematology, Genetics and Molecular Biology, on topics such as Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments and Chronic Lymphocytic Leukemia Research.
- World rank
- #62,381 of 7,710,434 ranked researchers
- Rank in United States
- #24,021 of 1,627,098
- Works
- 5,585
- Citations
- 273k
- Citations per work
- 48.9
What does Hagop M. Kantarjian research?
Hagop M. Kantarjian's work is mostly in Medicine (73%), Biochemistry, Genetics and Molecular Biology (9%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences4,08873.2%
- Medicine4,08873.2%
- Everything else97717.5%
- Life Sciences5199.3%
- 1Hematology36% of their works
- 2Genetics18% of their works
- 3Molecular Biology9% of their works
- 4Public Health, Environmental and Occupational Health9% of their works
- 5Oncology6% of their works
- 6Rheumatology5% of their works
Research topics
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
Which keywords describe Hagop M. Kantarjian's research?
The keywords of their largest research topics: Prognostic Factors, Acute Myeloid Leukemia, AML, BCR-ABL, Imatinib, Rituximab, Chronic Lymphocytic Leukemia and Genomic Aberrations.
- HDAC Inhibitors
- Lymphoma
- Fusion Genes
- JAK2 Mutation
- Childhood Cancer
- Genomic Aberrations
- Rituximab
- BCR-ABL
- AML
- Prognostic Factors
- Acute Myeloid Leukemia
- Imatinib
- Chronic Lymphocytic Leukemia
- Acute Lymphoblastic Leukemia
- Classification
- Myelofibrosis
- Hypereosinophilic Syndrome
- Molecular Profiling
- Histone Deacetylases
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 19 words, with their numbers
- Prognostic Factors5,4973 topics
- AML2,4341 topic
- Acute Myeloid Leukemia2,4341 topic
- BCR-ABL2,2931 topic
- Imatinib2,2931 topic
- Rituximab2,1992 topics
- Chronic Lymphocytic Leukemia1,7461 topic
- Genomic Aberrations1,7461 topic
- Acute Lymphoblastic Leukemia1,3171 topic
- Childhood Cancer1,3171 topic
- Classification1,1362 topics
- JAK2 Mutation8581 topic
- Myelofibrosis8581 topic
- Fusion Genes6831 topic
- Hypereosinophilic Syndrome6831 topic
- Lymphoma4531 topic
- Molecular Profiling4531 topic
- HDAC Inhibitors3041 topic
- Histone Deacetylases3041 topic
Where does Hagop M. Kantarjian work?
Hagop M. Kantarjian's main affiliation in the publication record is The University of Texas MD Anderson Cancer Center, United States.
How many publications and citations does Hagop M. Kantarjian have?
OpenAlex counts 5,585 works and 273,266 citations for Hagop M. Kantarjian, an h-index of 233, ranking #62,381 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Other researchers named Hagop M. Kantarjian
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Hagop M. Kantarjian. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.